Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional Results available

Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders

ClinicalTrials.gov ID: NCT02324673

Public ClinicalTrials.gov record NCT02324673. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 4, 2026, 8:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2 Study to Assess the Pharmacokinetics and Safety of Multiple Doses of Pharmaceutical Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Seizure Disorders

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 1/2, open-label trial designed to assess the pharmacokinetics, safety, tolerability, and preliminary efficacy of 3 multiple ascending doses of Cannabidiol Oral Solution in a sequential fashion. Participants will be pediatric (aged 1-17, inclusive), experiencing treatment-resistant seizures, and satisfy all inclusion/exclusion criteria.

Study identification

NCT ID
NCT02324673
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
INSYS Therapeutics Inc
Industry
Enrollment
61 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
1 Year to 17 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 12, 2015
Primary completion
May 8, 2016
Completion
May 8, 2016
Last update posted
Jun 22, 2017

2015 – 2016

United States locations

U.S. sites
10
U.S. states
9
U.S. cities
10
Facility City State ZIP Site status
University of California San Francisco Medical Center San Francisco California 94143
Miami Children's Hospital Miami Florida 33155
Child Neurology Center - NW F Pensacola Florida 32504
University of Chicago Medical Center Chicago Illinois 60637
Clinical Research Center of Nevada LLC Las Vegas Nevada 89104
Oregon Health Services University Portland Oregon 97239
Children's Hospital of Philadelphia Philadelphia Pennsylvania 19104
Le Bonheur Children's Hospital Memphis Tennessee 38103
Texas Scottish Rite Hospital for Children Dallas Texas 79219
Mary Bridge Children's Hospital Tacoma Washington 98403

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Recently updated Seizures trials

Other public records listing Seizures. Sorted by last update posted; newest first. Not a recommendation.

All Seizures trials →

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02324673, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 22, 2017 · Synced Sep 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02324673 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →